Abstract
Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide. Most available treatments contain estrogen, whether administered locally or systemically. Other treatment options include lubricants and moisturizers. These therapeutic approaches can provide temporary relief of some VVA symptoms while on therapy, but do not address the underlying condition, and they are not without potential side effects. However, promising new VVA therapies are in development that target the underlying condition with acceptable side-effect profiles. In this article, the benefits and drawbacks of current therapies and new treatments under development for VVA are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 141-151 |
| Number of pages | 11 |
| Journal | Expert Review of Obstetrics and Gynecology |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2011 |
Fingerprint
Keywords
- atrophic vaginitis
- dyspareunia
- vulvovaginal atrophy
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Reproductive Medicine
- Maternity and Midwifery
- Pediatrics, Perinatology, and Child Health
Cite this
Current treatment options for vulvovaginal atrophy. / Burich, Rebekah; Degregorio, Michael.
In: Expert Review of Obstetrics and Gynecology, Vol. 6, No. 2, 03.2011, p. 141-151.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current treatment options for vulvovaginal atrophy
AU - Burich, Rebekah
AU - Degregorio, Michael
PY - 2011/3
Y1 - 2011/3
N2 - Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide. Most available treatments contain estrogen, whether administered locally or systemically. Other treatment options include lubricants and moisturizers. These therapeutic approaches can provide temporary relief of some VVA symptoms while on therapy, but do not address the underlying condition, and they are not without potential side effects. However, promising new VVA therapies are in development that target the underlying condition with acceptable side-effect profiles. In this article, the benefits and drawbacks of current therapies and new treatments under development for VVA are discussed.
AB - Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide. Most available treatments contain estrogen, whether administered locally or systemically. Other treatment options include lubricants and moisturizers. These therapeutic approaches can provide temporary relief of some VVA symptoms while on therapy, but do not address the underlying condition, and they are not without potential side effects. However, promising new VVA therapies are in development that target the underlying condition with acceptable side-effect profiles. In this article, the benefits and drawbacks of current therapies and new treatments under development for VVA are discussed.
KW - atrophic vaginitis
KW - dyspareunia
KW - vulvovaginal atrophy
UR - http://www.scopus.com/inward/record.url?scp=79952959860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952959860&partnerID=8YFLogxK
U2 - 10.1586/eog.11.3
DO - 10.1586/eog.11.3
M3 - Article
AN - SCOPUS:79952959860
VL - 6
SP - 141
EP - 151
JO - Expert Review of Obstetrics and Gynecology
JF - Expert Review of Obstetrics and Gynecology
SN - 1747-4108
IS - 2
ER -